On May 5, 2020, the HonorHealth Research Institute and HonorHealth announced the successful enrollment on a novel combination of atovaquone and azithromycin in patients with moderate-to-severe COVID-19 infection. The clinical trial, conducted in collaboration with TGen was funded as an investigator-initiated clinical trial by HonorHealth Research Institute. This was one of 10 clinical trials that the HonorHealth Research Institute worked on related to COVID-19 to understand the biology, spread and treatment of COVID-19.